August 15, 2024CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business UpdateRead More Alle anzeigen 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 August 15, 2024CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma August 15, 2024CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board July 11, 2024CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech July 3, 2024CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities July 3, 2024GSK and CureVac to Restructure Collaboration into New Licensing Agreement June 24, 2024[English only] CureVac Announces Voting Results of General Meeting May 28, 2024CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK May 23, 2024CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update April 24, 2024CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update April 24, 2024CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK April 24, 2024CureVac Appoints Thaminda Ramanayake as New Chief Business Officer April 18, 2024CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 April 16, 2024CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines April 4, 2024CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK January 17, 2024[Form 6-K only / English only] CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock January 5, 2024CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform December 19, 2023CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE November 14, 2023CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update November 1, 2023CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK October 31, 2023CureVac to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November 14, 2023 September 28, 2023CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany September 12, 2023CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage August 17, 2023CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update August 1, 2023CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK July 14, 2023CureVac Announces Update to the Management Team July 13, 2023CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights June 20, 2023CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma June 20, 2023CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board June 19, 2023[English only] CureVac Announces Voting Results of General Meeting May 30, 2023CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update May 19, 2023CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech May 8, 2023CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK April 25, 2023CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update April 18, 2023CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023 March 28, 2023[English only] CureVac Announces Voting Results of Extraordinary General Meeting February 10, 2023CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares February 8, 2023CureVac Announces Pricing of Upsized Public Offering of Common Shares January 9, 2023CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 February 6, 2023CureVac Announces Proposed Public Offering of Common Shares February 1, 2023CureVac Welcomes Myriam Mendila as New Chief Development Officer January 6, 2023CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs January 31, 2023CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® December 14, 2022CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program January 30, 2023CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs November 16, 2022CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update November 11, 2022CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 November 10, 2022CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022 August 18, 2022CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update August 18, 2022CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate July 5, 2022CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech June 22, 2022CureVac Announces Voting Results of General Meeting June 8, 2022CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform June 8, 2022CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen May 25, 2022CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update May 25, 2022CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development April 28, 2022CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update April 22, 2022CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022 April 21, 2022CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study April 11, 2022CureVac and GSK Enter into Pandemic Preparedness Contract with German Government March 30, 2022CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV March 1, 2022CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® February 10, 2022CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK January 17, 2022CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry November 18, 2021CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update November 18, 2021CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine November 10, 2021CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response October 12, 2021CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology September 14, 2021CureVac Streamlines European Network for mRNA Product Manufacturing August 31, 2021CureVac’s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet August 30, 2021CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic August 16, 2021CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update August 16, 2021Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study June 30, 2021CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 June 30, 2021CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer® June 24, 2021CureVac Announces Voting Results of General Meeting June 23, 2021CureVac Provides Supervisory Board Update June 16, 2021CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV June 2, 2021CureVac Appoints Klaus Edvardsen as Chief Development Officer May 28, 2021CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation May 26, 2021CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates May 13, 2021Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study April 19, 2021CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic April 15, 2021CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 April 9, 2021CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 March 30, 2021Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV March 23, 2021CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study March 22, 2021CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a March 4, 2021CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV February 18, 2021CureVac to Participate in Upcoming Investor Conferences February 12, 2021CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV February 5, 2021CureVac to Host Conference Call on COVID-19 Partnership Update on February 5, 2021 February 5, 2021CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants February 4, 2021CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma February 4, 2021CureVac Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares February 3, 2021GSK and CureVac to develop next generation mRNA COVID-19 vaccines – joint press release February 2, 2021CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares February 1, 2021CureVac and Rentschler Biopharma ramp up Manufacturing of COVID-19 Vaccine, CVnCoV – joint press release January 28, 2021CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares January 25, 2021CureVac Announces Proposed Public Offering of Common Shares January 11, 2021CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection January 7, 2021CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV – joint press release December 21, 2020CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers December 14, 2020CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV December 9, 2020CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release December 8, 2020[German only] Moderne Wärme im Cyber Valley: Stadtwerke Tübingen versorgen neues Produktionsgebäude von CureVac – gemeinsame Pressemitteilung December 4, 2020CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer November 30, 2020CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020 November 26, 2020CureVac to Report Third Quarter and First Nine Months 2020 Financial Results and Business Updates on November 30, 2020 November 23, 2020CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release November 17, 2020CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV November 16, 2020European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV November 12, 2020CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Suitable for Standard Fridge Temperature Logistics November 10, 2020CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV November 2, 2020CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV October 23, 2020CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV September 29, 2020CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate September 4, 2020CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development and Production Capacity Expansion August 20, 2020CureVac and European Commission in Advanced Discussions to Supply up to 405 million doses of potential mRNA-based COVID-19 Vaccine August 18, 2020CureVac Announces Closing of Initial Public Offering August 14, 2020CureVac Announces Pricing of Initial Public Offering August 10, 2020CureVac Announces Proposed Initial Public Offering of Common Shares August 4, 2020CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer July 21, 2020CureVac Raises a Total of USD 640 Million in Private Financing Round July 20, 2020GSK and CureVac announce strategic mRNA technology collaboration July 6, 2020Germany: EIB and European Commission provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing July 1, 2020Please note: Currently, there is no possibility to purchase shares of CureVac AG. Offers to purchase shares in CureVac AG are fraudulent. June 17, 2020CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate June 15, 2020German Federal Government invests 300 Million Euros in CureVac May 14, 2020CureVac’s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate April 2, 2020Jean Stéphenne Elected as New Chairman of the Supervisory Board of CureVac March 17, 2020COVID-19: Conference Call on Current Developments March 16, 2020CureVac announces leadership update March 15, 2020CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide March 11, 2020Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG March 3, 2020CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force February 26, 2020CureVac Appoints Alan Kimura, MD, PhD as Head of the Newly Created Department “Rare Diseases” January 31, 2020CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019 January 7, 2020CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study December 19, 2019Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics December 2, 2019CureVac Granted Manufacturing Authorization for its Third GMP Production Suite November 20, 2019CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference October 24, 2019CureVac to Present CV8102 Data at SITC Conference August 13, 2019CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University July 12, 2019CureVac to Participate in Two Panels at the ROTH RNA Revolution Conference July 1, 2019European Commission Appoints CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, to the European Innovation Council Advisory Board June 24, 2019CureVac Welcomes Two Members to its Supervisory Board June 13, 2019CureVac Receives Grants for Three Patents Regarding Intratumoral Application of RNA May 20, 2019CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary April 16, 2019CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies April 9, 2019CureVac to Participate in Upcoming Investor Conferences March 21, 2019CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019 February 27, 2019CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases February 19, 2019CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference February 4, 2019CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical January 28, 2019CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer January 8, 2019CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV November 21, 2018CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference November 7, 2018CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the 2018 Society for Immunotherapy of Cancer Annual Meeting November 7, 2018University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator October 23, 2018CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA June 12, 2018CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations May 8, 2018CureVac Announces New Management Structure March 22, 2018CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA February 18, 2018CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria January 18, 2018CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics January 10, 2018CureVac Highlights Key 2018 Corporate Milestones and Outlook January 4, 2018CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics December 28, 2017CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017 November 13, 2017CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs November 6, 20175th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration October 29, 2017CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics October 27, 2017CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors October 27, 2017Publication in npj Vaccines Demonstrates CureVac’s RNActive® Vaccine is Superior to Licensed Vaccines October 17, 2017Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines August 15, 2017Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors July 31, 20175th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs July 26, 2017CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine July 20, 2017CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies June 26, 2017CureVac Expands GMP Production Capacities for RNA Products June 13, 2017CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines May 19, 2017CureVac to Present at Upcoming International Investor Conferences May 2, 2017CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary January 20, 2017CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group January 11, 2017CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference December 5, 2016Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant November 8, 2016CureVac Secures an Additional $29.5 Million From Two New Investors November 8, 2016CureVac Receives Broad Patent for RNAntibody® Technology October 11, 2016CureVac Appoints Pierre Kemula as Chief Financial Officer July 14, 2016Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines March 30, 2016CureVac Appoints Leading Experts to its Scientific Advisory Board March 18, 2016CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion February 18, 2016CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances January 6, 2016CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference November 3, 2015CureVac raises $110 Million in a private placement September 10, 2015IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates September 10, 2015CureVac Establishes U.S. Operations in Cambridge, MA September 3, 2015CureVac to Present at BioCentury’s 22nd Annual NewsMakers in the Biotech Industry Conference August 4, 2015Collaboration to Develop mRNA Vaccines Expands July 24, 2015CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs July 7, 2015CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer March 5, 2015The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology September 18, 2014Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy December 16, 2013CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment November 5, 20131st International mRNA Health Conference in Tübingen Heralds a New Era in Modern Medicine November 4, 2013CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer October 3, 2013CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine April 10, 2013CureVac’s CEO Ingmar Hoerr is Keynote Speaker at the Cancer Vaccines and Gene Therapy Meeting 2013 in Philadelphia March 27, 2013CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer November 25, 2012Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac’s RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection September 18, 2012CureVac Secures €80 Million in Series D Financing November 7, 2011CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) Media Contacts Dr. Sarah Fakih Vice President Corporate Communications & Investor Relations T +49 7071 9883 – 1298 M +49 160 – 90496949 E-Mail Patrick Perez Junior PR Manager T +49 7071 9883 – 1831 M +49 151 – 14115247 E-Mail August 15, 2024CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business UpdateRead More Media Contacts Dr. Sarah Fakih Vice President Corporate Communications & Investor Relations T +49 7071 9883 – 1298 M +49 160 – 90496949 E-Mail Patrick Perez Junior PR Manager T +49 7071 9883 – 1831 M +49 151 – 14115247 E-Mail Alle anzeigen 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 August 15, 2024CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma August 15, 2024CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board July 11, 2024CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech July 3, 2024CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities July 3, 2024GSK and CureVac to Restructure Collaboration into New Licensing Agreement June 24, 2024[English only] CureVac Announces Voting Results of General Meeting May 28, 2024CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK May 23, 2024CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update April 24, 2024CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update April 24, 2024CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK April 24, 2024CureVac Appoints Thaminda Ramanayake as New Chief Business Officer April 18, 2024CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 April 16, 2024CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines April 4, 2024CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK January 17, 2024[Form 6-K only / English only] CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock January 5, 2024CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform December 19, 2023CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE November 14, 2023CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update November 1, 2023CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK October 31, 2023CureVac to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November 14, 2023 September 28, 2023CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany September 12, 2023CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage August 17, 2023CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update August 1, 2023CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK July 14, 2023CureVac Announces Update to the Management Team July 13, 2023CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights June 20, 2023CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma June 20, 2023CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board June 19, 2023[English only] CureVac Announces Voting Results of General Meeting May 30, 2023CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update May 19, 2023CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech May 8, 2023CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK April 25, 2023CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update April 18, 2023CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023 March 28, 2023[English only] CureVac Announces Voting Results of Extraordinary General Meeting February 10, 2023CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares February 8, 2023CureVac Announces Pricing of Upsized Public Offering of Common Shares January 9, 2023CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 February 6, 2023CureVac Announces Proposed Public Offering of Common Shares February 1, 2023CureVac Welcomes Myriam Mendila as New Chief Development Officer January 6, 2023CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs January 31, 2023CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® December 14, 2022CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program January 30, 2023CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs November 16, 2022CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update November 11, 2022CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 November 10, 2022CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022 August 18, 2022CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update August 18, 2022CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate July 5, 2022CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech June 22, 2022CureVac Announces Voting Results of General Meeting June 8, 2022CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform June 8, 2022CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen May 25, 2022CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update May 25, 2022CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development April 28, 2022CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update April 22, 2022CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022 April 21, 2022CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study April 11, 2022CureVac and GSK Enter into Pandemic Preparedness Contract with German Government March 30, 2022CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV March 1, 2022CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® February 10, 2022CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK January 17, 2022CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry November 18, 2021CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update November 18, 2021CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine November 10, 2021CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response October 12, 2021CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology September 14, 2021CureVac Streamlines European Network for mRNA Product Manufacturing August 31, 2021CureVac’s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet August 30, 2021CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic August 16, 2021CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update August 16, 2021Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study June 30, 2021CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 June 30, 2021CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer® June 24, 2021CureVac Announces Voting Results of General Meeting June 23, 2021CureVac Provides Supervisory Board Update June 16, 2021CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV June 2, 2021CureVac Appoints Klaus Edvardsen as Chief Development Officer May 28, 2021CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation May 26, 2021CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates May 13, 2021Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study April 19, 2021CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic April 15, 2021CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 April 9, 2021CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 March 30, 2021Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV March 23, 2021CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study March 22, 2021CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a March 4, 2021CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV February 18, 2021CureVac to Participate in Upcoming Investor Conferences February 12, 2021CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV February 5, 2021CureVac to Host Conference Call on COVID-19 Partnership Update on February 5, 2021 February 5, 2021CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants February 4, 2021CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma February 4, 2021CureVac Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares February 3, 2021GSK and CureVac to develop next generation mRNA COVID-19 vaccines – joint press release February 2, 2021CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares February 1, 2021CureVac and Rentschler Biopharma ramp up Manufacturing of COVID-19 Vaccine, CVnCoV – joint press release January 28, 2021CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares January 25, 2021CureVac Announces Proposed Public Offering of Common Shares January 11, 2021CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection January 7, 2021CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV – joint press release December 21, 2020CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers December 14, 2020CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV December 9, 2020CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release December 8, 2020[German only] Moderne Wärme im Cyber Valley: Stadtwerke Tübingen versorgen neues Produktionsgebäude von CureVac – gemeinsame Pressemitteilung December 4, 2020CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer November 30, 2020CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020 November 26, 2020CureVac to Report Third Quarter and First Nine Months 2020 Financial Results and Business Updates on November 30, 2020 November 23, 2020CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release November 17, 2020CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV November 16, 2020European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV November 12, 2020CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Suitable for Standard Fridge Temperature Logistics November 10, 2020CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV November 2, 2020CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV October 23, 2020CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV September 29, 2020CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate September 4, 2020CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development and Production Capacity Expansion August 20, 2020CureVac and European Commission in Advanced Discussions to Supply up to 405 million doses of potential mRNA-based COVID-19 Vaccine August 18, 2020CureVac Announces Closing of Initial Public Offering August 14, 2020CureVac Announces Pricing of Initial Public Offering August 10, 2020CureVac Announces Proposed Initial Public Offering of Common Shares August 4, 2020CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer July 21, 2020CureVac Raises a Total of USD 640 Million in Private Financing Round July 20, 2020GSK and CureVac announce strategic mRNA technology collaboration July 6, 2020Germany: EIB and European Commission provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing July 1, 2020Please note: Currently, there is no possibility to purchase shares of CureVac AG. Offers to purchase shares in CureVac AG are fraudulent. June 17, 2020CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate June 15, 2020German Federal Government invests 300 Million Euros in CureVac May 14, 2020CureVac’s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate April 2, 2020Jean Stéphenne Elected as New Chairman of the Supervisory Board of CureVac March 17, 2020COVID-19: Conference Call on Current Developments March 16, 2020CureVac announces leadership update March 15, 2020CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide March 11, 2020Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG March 3, 2020CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force February 26, 2020CureVac Appoints Alan Kimura, MD, PhD as Head of the Newly Created Department “Rare Diseases” January 31, 2020CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019 January 7, 2020CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study December 19, 2019Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics December 2, 2019CureVac Granted Manufacturing Authorization for its Third GMP Production Suite November 20, 2019CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference October 24, 2019CureVac to Present CV8102 Data at SITC Conference August 13, 2019CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University July 12, 2019CureVac to Participate in Two Panels at the ROTH RNA Revolution Conference July 1, 2019European Commission Appoints CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, to the European Innovation Council Advisory Board June 24, 2019CureVac Welcomes Two Members to its Supervisory Board June 13, 2019CureVac Receives Grants for Three Patents Regarding Intratumoral Application of RNA May 20, 2019CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary April 16, 2019CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies April 9, 2019CureVac to Participate in Upcoming Investor Conferences March 21, 2019CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019 February 27, 2019CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases February 19, 2019CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference February 4, 2019CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical January 28, 2019CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer January 8, 2019CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV November 21, 2018CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference November 7, 2018CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the 2018 Society for Immunotherapy of Cancer Annual Meeting November 7, 2018University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator October 23, 2018CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA June 12, 2018CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations May 8, 2018CureVac Announces New Management Structure March 22, 2018CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA February 18, 2018CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria January 18, 2018CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics January 10, 2018CureVac Highlights Key 2018 Corporate Milestones and Outlook January 4, 2018CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics December 28, 2017CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017 November 13, 2017CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs November 6, 20175th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration October 29, 2017CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics October 27, 2017CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors October 27, 2017Publication in npj Vaccines Demonstrates CureVac’s RNActive® Vaccine is Superior to Licensed Vaccines October 17, 2017Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines August 15, 2017Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors July 31, 20175th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs July 26, 2017CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine July 20, 2017CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies June 26, 2017CureVac Expands GMP Production Capacities for RNA Products June 13, 2017CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines May 19, 2017CureVac to Present at Upcoming International Investor Conferences May 2, 2017CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary January 20, 2017CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group January 11, 2017CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference December 5, 2016Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant November 8, 2016CureVac Secures an Additional $29.5 Million From Two New Investors November 8, 2016CureVac Receives Broad Patent for RNAntibody® Technology October 11, 2016CureVac Appoints Pierre Kemula as Chief Financial Officer July 14, 2016Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines March 30, 2016CureVac Appoints Leading Experts to its Scientific Advisory Board March 18, 2016CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion February 18, 2016CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances January 6, 2016CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference November 3, 2015CureVac raises $110 Million in a private placement September 10, 2015IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates September 10, 2015CureVac Establishes U.S. Operations in Cambridge, MA September 3, 2015CureVac to Present at BioCentury’s 22nd Annual NewsMakers in the Biotech Industry Conference August 4, 2015Collaboration to Develop mRNA Vaccines Expands July 24, 2015CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs July 7, 2015CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer March 5, 2015The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology September 18, 2014Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy December 16, 2013CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment November 5, 20131st International mRNA Health Conference in Tübingen Heralds a New Era in Modern Medicine November 4, 2013CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer October 3, 2013CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine April 10, 2013CureVac’s CEO Ingmar Hoerr is Keynote Speaker at the Cancer Vaccines and Gene Therapy Meeting 2013 in Philadelphia March 27, 2013CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer November 25, 2012Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac’s RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection September 18, 2012CureVac Secures €80 Million in Series D Financing November 7, 2011CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC)
